文献速递冠心病血脂与心血管预防

1型糖尿病血糖控制、心脏自身免疫与远期心血管疾病风险

Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus.
PubMed 文献 · Circulation · 2019-01-01

基于DCCT/EDIC队列,比较HbA1c≥9.0%与≤7.0%的1型糖尿病患者,发现血糖控制差者心脏自身抗体阳性率显著升高,且≥2种抗体阳性与26年随访期间心血管事件风险及冠状动脉钙化增加相关。

要点

  • 1型糖尿病血糖控制差与心脏自身抗体产生相关。
  • ≥2种心脏自身抗体阳性与远期心血管事件风险显著增加相关。
  • 自身抗体阳性者高敏C反应蛋白水平更高,提示炎症通路参与。

核心结论

  • 1型糖尿病中血糖控制差与心脏自身免疫相关,心脏自身抗体阳性与数十年后心血管疾病风险增加相关,提示自身免疫机制可能通过炎症通路参与1型糖尿病心血管并发症。

研究设计与样本

  • 纵向样本分析来自DCCT队列,选取DCCT期间平均HbA1c≥9.0%(n=83)和≤7.0%(n=83)的1型糖尿病患者,随访EDIC观察性研究。
  • 同时测量匹配的2型糖尿病患者(HbA1c≥9.0% n=70,≤7.0% n=140)及Chagas心肌病对照(n=51)的心脏自身抗体。
  • 评估冠状动脉钙化(EDIC第7-9年测量一次)、高敏C反应蛋白(EDIC第4-6年测量)及中位26年随访期间的心血管事件。

主要发现

  • DCCT期间HbA1c≥9.0%组心脏自身抗体水平显著高于≤7.0%组,两组随时间分别呈进行性升高和降低(P<0.001)。
  • HbA1c≥9.0%组中≥1、≥2、≥3种心脏自身抗体阳性的比例分别为46%、22%、11%,与Chagas心肌病患者相似,而≤7.0%组分别为2%、1%、0%。
  • 2型糖尿病中血糖控制与自身抗体阳性率无关。
  • DCCT期间≥2种自身抗体阳性与心血管事件风险增加相关(6例中4例;HR 16.1,95%CI 3.0-88.2),多因素分析中与可检测的冠状动脉钙化相关(31例中13例;OR 60.1,95%CI 8.4-410.0)。
  • ≥2种自身抗体阳性者随后高敏C反应蛋白水平升高(6.0 mg/L vs ≤1种者1.4 mg/L;P=0.003)。

临床怎么用

  • 对于1型糖尿病患者,尤其血糖控制差者,可关注心脏自身抗体作为心血管风险分层的潜在标志物。
  • 自身抗体阳性提示炎症通路激活,可能为未来靶向抗炎或免疫调节治疗提供依据。

局限性

  • 心脏自身抗体仅在DCCT/EDIC特定样本中测量,样本量有限。
  • 冠状动脉钙化仅测量一次,高敏C反应蛋白测量时间窗有限。
  • 研究为观察性分析,不能确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Poor glycemic control is associated with increased risk of cardiovascular disease (CVD) in type 1 diabetes mellitus (T1DM); however, little is known about mechanisms specific to T1DM. In T1DM, myocardial injury can induce persistent cardiac autoimmunity. Chronic hyperglycemia causes myocardial injury, raising the possibility that hyperglycemia-induced cardiac autoimmunity could contribute to long-term CVD complications in T1DM. METHODS: We measured the prevalence and profiles of cardiac autoantibodies (AAbs) in longitudinal samples from the DCCT (Diabetes Control and Complications Trial) in participants with mean hemoglobin A1c (HbA1c) ≥9.0% (n=83) and ≤7.0% (n=83) during DCCT. We assessed subsequent coronary artery calcification (measured once during years 7-9 in the post-DCCT EDIC [Epidemiology of Diabetes Interventions and Complications] observational study), high-sensitivity C-reactive protein (measured during EDIC years 4-6), and CVD events (defined as nonfatal myocardial infarction, stroke, death resulting from CVD, heart failure, or coronary artery bypass graft) over a 26-year median follow-up. Cardiac AAbs were also measured in matched patients with type 2 diabetes mellitus with HbA1c ≥9.0% (n=70) and ≤7.0% (n=140) and, as a control for cardiac autoimmunity, patients with Chagas cardiomyopathy (n=51). RESULTS: Apart from HbA1c levels, the DCCT groups shared similar CVD risk factors at the beginning and end of DCCT. The DCCT HbA1c ≥9.0% group showed markedly higher cardiac AAb levels than the HbA1c ≤7.0% group during DCCT, with a progressive increase and decrease in AAb levels over time in the 2 groups, respectively ( P<0.001). In the HbA1c ≥9.0% group, 46%, 22%, and 11% tested positive for ≥1, ≥2, and ≥3 different cardiac AAb types, respectively, similar to patients with Chagas cardiomyopathy, compared with 2%, 1%, and 0% in the HbA1c ≤7.0% group. Glycemic control was not associated with AAb prevalence in type 2 diabetes mellitus. Positivity for ≥2 AAbs during DCCT was associated with increased risk of CVD events (4 of 6; hazard ratio, 16.1; 95% CI, 3.0-88.2) and, in multivariable analyses, with detectable coronary artery calcification (13 of 31; odds ratio, 60.1; 95% CI, 8.4-410.0). Patients with ≥2 AAbs subsequently also showed elevated high-sensitivity C-reactive protein levels (6.0 mg/L versus 1.4 mg/L in patients with ≤1 AAbs; P=0.003). CONCLUSIONS: Poor glycemic control is associated with cardiac autoimmunity in T1DM. Furthermore, cardiac AAb positivity is associated with an increased risk of CVD decades later, suggesting a role for autoimmune mechanisms in the development of CVD in T1DM, possibly through inflammatory pathways.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Sousa GR, Pober D, Galderisi A, et al. Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus. Circulation. 2019. PMID: 30586738. doi:10.1161/CIRCULATIONAHA.118.036068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。